Urothelial Cancer | Page 2 | Pfizer Información Médica

Materiales de Congresos

La información de esta página es seleccionada de materiales de congresos, áreas terapéuticas y de enfermedades. No pretende servir como una descripción general completa de todos los contenidos mencionados

Volver al áreas de Enfermedades

Póster

Liu FX, Costantino H, Ike C, Gupta S, Bhanegaonkar A, Thakkar S, Devgan G, Katzenstein H Junio 4, 2022 ASCO 2022 Cáncer Urotelial

Evaluating Oncologists’ Practice Patterns and Decision-Making in Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC): The US Physician PARADIGM Study (part 2)

Ver Presentación

Póster

Bellmunt J, Powles T, Climent Duran MA, Sridhar SS, Gurney H, Costa N, di Pietro A, Huang B, Gupta S, Grivas P Junio 4, 2022 ASCO 2022 Cáncer Urotelial

Long-Term Outcomes in Patients With Advanced Urothelial Carcinoma who Received Avelumab First-Line Maintenance With or Without Second-Line Treatment: Exploratory Analyses From JAVELIN Bladder 100

Ver Presentación Ver resumen en lenguaje sencillo

Presentación Oral

Powles T, Sridhar SS, Bellmunt J, Sternberg CN, Grivas P, Hunter E, Dezfouli M, Salter M, Powel R, Ding A, Green J, Akoulitchev A, Amezquita R, Ching K, Pu J, Deng S, di Pietro A, Davis CB Septiembre 10, 2022 ESMO 2022 Cáncer Urotelial

Genomic Biomarkers in Peripheral Blood (PB) From Patients (Pts) Enrolled in the JAVELIN Bladder 100 Trial of Avelumab First-Line (1L) Maintenance in Advanced Urothelial Carcinoma (aUC)

Ver Presentación

Póster

Aragon-Ching JB, Grivas P, Loriot Y, Bellmunt J, Wang J, Michelon E, di Pietro A, Powles T, Sridhar SS Septiembre 12, 2022 ESMO 2022 Cáncer Urotelial

Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From Patients With ≥12 Months of Treatment in JAVELIN Bladder 100

Ver Presentación Ver resumen en lenguaje sencillo

Póster

Lapuente M, Milloy N, Berry M, Montgomery R, Bleasdale C, Kluth C, Kirker M, Kearney M, Costa N, Chang J Septiembre 12, 2022 ESMO 2022 Cáncer Urotelial

Evaluating Real-World Caregiver Involvement From a Survey of Patients With Metastatic Urothelial Cancer (mUC) Receiving Systemic Anticancer Treatment in France, Germany, Italy, Spain, and the UK (Eu5)

Ver Presentación

Póster

Barthelemy P, Thibault C, Voog E, Eymard JC, Ravaud A, Flechon A, Abraham C, Hilgers W, Le Moulec S, Chasseray M, Pouessel D, Amela E, Lorgis V, Nicolas E, Kazan E, Denechere G, Solbes M-N, Lambert P, Loriot Y Septiembre 12, 2022 ESMO 2022 Cáncer Urotelial

Preliminary Results From AVENANCE, an Ongoing, Noninterventional Real-World, Ambispective Study of Avelumab First-Line Maintenance Treatment in Patients With Locally Advanced or Metastatic Urothelial Carcinoma

Ver Presentación Ver resumen en lenguaje sencillo

Presentación Oral

Eto M, Desai C, Park SH, Tsuchiya N, Su P-J, Chan TTW, Gurney H, Gao S, Wang J, Sandner R, di Pietro A, Lee J-L Diciembre 2, 2022 ESMO Asia Cáncer Urotelial

Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Longer-Term Follow-Up From the Asian Subgroup of the JAVELIN Bladder 100 Trial

Ver Presentación Ver resumen en lenguaje sencillo

Póster

Milloy N, Berry M, Montgomery R, Kluth C, Bleasdale C, Kirker M, Kearney M, Mohamed W, Costa N, Chang J Diciembre 3, 2022 ESMO Asia Cáncer Urotelial

First-Line (1L) Treatment Patterns and Criteria Used to Determine Platinum Eligibility (PE) in Platinum-Eligible and -Ineligible Patients With Metastatic Urothelial Cancer (mUC) in South Korea and Taiwan

Ver Presentación